ERBB2 and neoplasm: The UK data from the NHSBSP national audit, which allows detailed examination of changes in clinical practice following publication of randomized trials, indicates that there has been a reluctance to follow suit, despite guidance from the Association of Breast Surgery27, and NICE that recommends that further axillary treatment is no longer mandatory in patients who are receiving breast conservation with whole-breast radiotherapy, who are postmenopausal, and have T1, grade 1 or 2, oestrogen receptor-positive and HER2-negative tumours.2